Encephalopathy cost-effectiveness of therapy

Revision as of 20:31, 27 July 2012 by Michael Maddaleni (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Encephalopathy

Home

Patient Information

Overview

Classification

Pathophysiology

Causes

Differentiating Encephalopathy from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Electroencephalogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Encephalopathy cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Encephalopathy cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Encephalopathy cost-effectiveness of therapy

CDC on Encephalopathy cost-effectiveness of therapy

Encephalopathy cost-effectiveness of therapy in the news

Blogs on Encephalopathy cost-effectiveness of therapy

Directions to Hospitals Treating Encephalopathy

Risk calculators and risk factors for Encephalopathy cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Govindavarjhulla, M.B.B.S. [2]

Overview

Encephalopathy in its very early stages is cost effective. Early intervention relieves forthcoming complications and the costs that would have come along with them.

Financial Costs

  • Cost effectiveness of various therapies depends on the condition.
  • Hypothermia for neonatal encephalopathy - The incremental cost per disability-free life year gained was $28,124 (£19,931 ; €26,920) as per the data of 2006 Organisation for Economic Co-operation and Development (OECD). [1]
  • Detection of minimal hepatic encephalopathy, especially using the inhibitory control test, and subsequent treatment with lactulose could substantially reduce societal costs by preventing motor vehicle accident. Net program savings over 5 years ranged from $1.7 to 3.6 million.[2]

References

  1. Regier DA, Petrou S, Henderson J; et al. (2010). "Cost-effectiveness of therapeutic hypothermia to treat neonatal encephalopathy". Value Health. 13 (6): 695–702. doi:10.1111/j.1524-4733.2010.00731.x. PMID 20561343.
  2. Bajaj JS, Pinkerton SD, Sanyal AJ, Heuman DM (2012). "Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis". Hepatology. 55 (4): 1164–71. doi:10.1002/hep.25507. PMID 22135042. Unknown parameter |month= ignored (help)

Template:WH Template:WS